Horse tranquilliser trial is awarded $750,000 grant for Parkinson’s research

News

Author: Simge Eva DoganPublished: 26 July 2018

Parkinson's LifePrep: Parkinson's LifeCook: Parkinson's LifeServes:

ketamine

Researchers at the University of Arizona College of Medicine, Tucson, US, will be trialling ketamine – a recreational drug previously used to medicate people with depression – as a treatment for Parkinson’s.

The research – led by Dr Scott Sherman – is being supported with a three-year grant of $750,000 from the Arizona Biomedical Research Commission.

The initial clinical trial will test the effect of ketamine for treating dyskinesia in 10 patients. In addition, the researchers will carry out a separate rodent study to examine how the drug affects the brain.

Dr Scott Sherman, a neurologist at the University of Arizona College of Medicine, said: “Ketamine has been long overlooked. Now it could prove very useful for Parkinson’s patients.”

For information on the latest Parkinson’s research please visit the European Parkinson’s Disease Association website.

For more information on this article click here.

Go Back

Share this story

Comments


Related articles


Global update

Judas Priest guitarist raises $150,000 for Parkinson’s

Rock guitarist Glenn Tipton thanks fans for their generosity

READ MORE
Canadian musician Joseph Shabason

Interviews

‘My album was an excuse to talk to my mother about Parkinson’s’

Canadian musician Joseph Shabason tells us about his album on Parkinson’s

READ MORE
threesixfives_brand_graphic

Resources & Tools

Emma Lawton launches crowdfunding campaign for Parkinson’s video website

Help fund peer-led support websites ‘threesixfives’

READ MORE